Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Sgl Resources Limited Share Price

₹ 3.14 0.00 (0.00%)

Apr 15 2025 12:00 AM IT - Software NSE: SGLRES

Sgl Resources Limited Share Price Update

As of the latest trading session, Sgl Resources Limited share price is currently at 3.14, which is up by 0.00 from its previous closing. Today, the stock has fluctuated between 3.03 and 3.14. Over the past year, Sgl Resources Limited has achieved a return of -47.16 %. In the last month alone, the return has been -16.98 %. Read More...

Sgl Resources Limited Performance

Day Range

Low3.03 High3.14

3.14

52 Week Range

Low 2.83 High 10.66

3.14

Sgl Resources Limited Share Price

526544

SGLRES

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

3.03 Prev. Close

3.14 Volume (Shares)

200570.00

Total traded value

6.15 Upper Circuit

3.20 Lower Circuit

3.08

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Sgl Resources Limited Fundamentals

(Standalone)

Market Cap (Cr)	21.76
PE Ratio (TTM)	28.00
Book Value / Share	7.40
Beta	0.09

ROE	1.89%
EPS (TTM)	0.11
Dividend Yield	0.00%
Net Profit Qtr (Cr)	0.61

Sgl Resources Limited Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	7.97
Operating Expense	7.47
Net Profit	0.61
Net Profit Margin (%)	7.65
Earnings Per Share (EPS)	0.02
EBITDA	1.70
Effective Tax Rate (%)	25.60

Particulars	SEP 2024 (Values in Cr)
Revenue	21.55
Operating Expense	21.46
Net Profit	0.49
Net Profit Margin (%)	2.27
Earnings Per Share (EPS)	0.03
EBITDA	19.97
Effective Tax Rate (%)	26.86

Particulars	JUN 2024 (Values in Cr)
Revenue	17.75
Operating Expense	16.84
Net Profit	0.47
Net Profit Margin (%)	2.64
Earnings Per Share (EPS)	0.03
EBITDA	1.69
Effective Tax Rate (%)	54.90

Particulars	MAR 2024 (Values in Cr)
Revenue	19.28
Operating Expense	18.54
Net Profit	1.13
Net Profit Margin (%)	5.86
Earnings Per Share (EPS)	0.16
EBITDA	1.80
Effective Tax Rate (%)	-15.46

Particulars	DEC 2023 (Values in Cr)
Revenue	3.34
Operating Expense	3.27
Net Profit	0.15
Net Profit Margin (%)	4.49
Earnings Per Share (EPS)	0.02
EBITDA	0.86
Effective Tax Rate (%)	23.80

Particulars	MAR 2024 (Values in Cr)
Revenue	29.53
Operating Expense	28.63
Net Profit	1.62
Net Profit Margin (%)	5.48
Earnings Per Share (EPS)	0.23
EBITDA	4.43
Effective Tax Rate (%)	-5.88

Particulars	MAR 2023 (Values in Cr)
Revenue	17.00
Operating Expense	16.38
Net Profit	0.58
Net Profit Margin (%)	3.41
Earnings Per Share (EPS)	0.08
EBITDA	3.95
Effective Tax Rate (%)	43.68

Particulars	MAR 2022 (Values in Cr)
Revenue	33.03
Operating Expense	30.83
Net Profit	1.97
Net Profit Margin (%)	5.96
Earnings Per Share (EPS)	0.30
EBITDA	5.35
Effective Tax Rate (%)	24.80

Particulars	MAR 2021 (Values in Cr)
Revenue	43.38
Operating Expense	41.04
Net Profit	2.03
Net Profit Margin (%)	4.67
Earnings Per Share (EPS)	0.30
EBITDA	5.48
Effective Tax Rate (%)	26.18

Particulars	MAR 2020 (Values in Cr)
Revenue	52.52
Operating Expense	50.49
Net Profit	1.74
Net Profit Margin (%)	3.31
Earnings Per Share (EPS)	0.35
EBITDA	5.16
Effective Tax Rate (%)	30.40

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	12.42
ROE %	1.89
ROCE %	2.35
Total Debt to Total Equity	0.69
EBITDA Margin	15.68

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	12.26
ROE %	0.69
ROCE %	2.32
Total Debt to Total Equity	0.50
EBITDA Margin	24.53

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	12.15
ROE %	2.76
ROCE %	4.33
Total Debt to Total Equity	0.45
EBITDA Margin	16.80

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	11.67
ROE %	3.56
ROCE %	5.81
Total Debt to Total Equity	0.46
EBITDA Margin	13.30

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	11.26
ROE %	3.48
ROCE %	6.72
Total Debt to Total Equity	0.36
EBITDA Margin	10.42

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	12.43
ROE %	1.89
ROCE %	2.35
Total Debt to Total Equity	0.69
EBITDA Margin	15.68

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	12.27
ROE %	0.69
ROCE %	2.32
Total Debt to Total Equity	0.50
EBITDA Margin	24.59

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	12.16
ROE %	2.77
ROCE %	4.33
Total Debt to Total Equity	0.45
EBITDA Margin	16.80

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	11.68
ROE %	3.58
ROCE %	5.82
Total Debt to Total Equity	0.46
EBITDA Margin	13.32

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	11.27
ROE %	3.48
ROCE %	6.71
Total Debt to Total Equity	0.36
EBITDA Margin	10.42

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	10.09
Total Assets	191.96
Total Liabilities	191.96
Total Equity	86.11
Share Outstanding	69307248
Price to Book Ratio	0.51
Return on Assets (%)	0.84
Return on Capital (%)	1.08

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	7.87
Total Assets	161.21
Total Liabilities	161.21
Total Equity	84.97
Share Outstanding	69307248
Price to Book Ratio	0.54
Return on Assets (%)	0.35
Return on Capital (%)	0.42

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	0.12
Total Assets	142.40
Total Liabilities	142.40
Total Equity	84.23
Share Outstanding	69387000
Price to Book Ratio	1.32
Return on Assets (%)	1.37
Return on Capital (%)	1.71

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	0.17
Total Assets	115.31
Total Liabilities	115.31
Total Equity	57.69
Share Outstanding	49419518
Price to Book Ratio	1.24
Return on Assets (%)	1.75
Return on Capital (%)	2.27

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.14
Total Assets	90.45
Total Liabilities	90.45
Total Equity	55.67
Share Outstanding	49419518
Price to Book Ratio	1.60
Return on Assets (%)	1.91
Return on Capital (%)	2.37

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	10.09
Total Assets	191.91
Total Liabilities	191.91
Total Equity	86.16
Share Outstanding	69307248
Price to Book Ratio	0.51
Return on Assets (%)	0.84
Return on Capital (%)	1.08

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	7.87
Total Assets	161.26
Total Liabilities	161.26
Total Equity	85.02
Share Outstanding	69307248
Price to Book Ratio	0.54
Return on Assets (%)	0.36
Return on Capital (%)	0.42

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	0.11
Total Assets	142.45
Total Liabilities	142.45
Total Equity	84.28
Share Outstanding	69387000
Price to Book Ratio	1.32
Return on Assets (%)	1.38
Return on Capital (%)	1.72

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	0.17
Total Assets	115.35
Total Liabilities	115.35
Total Equity	57.72
Share Outstanding	49419518
Price to Book Ratio	1.24
Return on Assets (%)	1.75
Return on Capital (%)	2.27

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.14
Total Assets	90.48
Total Liabilities	90.48
Total Equity	55.70
Share Outstanding	49419518
Price to Book Ratio	1.60
Return on Assets (%)	1.92
Return on Capital (%)	2.38

Particulars	MAR 2024 (Values in Cr)
Net Income	1.52
Cash from Operations	6.58
Cash from Investing	-14.53
Cash from Financing	8.18
Net change in Cash	-0.21
Free Cash Flow	6.61

Particulars	MAR 2023 (Values in Cr)
Net Income	1.02
Cash from Operations	0.61
Cash from Investing	-21.76
Cash from Financing	21.82
Net change in Cash	0.21
Free Cash Flow	1.60

Particulars	MAR 2022 (Values in Cr)
Net Income	2.60
Cash from Operations	-1.88
Cash from Investing	-18.01
Cash from Financing	19.84
Net change in Cash	-0.04
Free Cash Flow	-0.98

Particulars	MAR 2021 (Values in Cr)
Net Income	2.74
Cash from Operations	1.89
Cash from Investing	-14.13
Cash from Financing	12.26
Net change in Cash	0.02
Free Cash Flow	2.42

Particulars	MAR 2020 (Values in Cr)
Net Income	2.49
Cash from Operations	-3.45
Cash from Investing	-12.27
Cash from Financing	15.82
Net change in Cash	0.09
Free Cash Flow	-2.77

Particulars	MAR 2024 (Values in Cr)
Net Income	1.52
Cash from Operations	6.58
Cash from Investing	-14.53
Cash from Financing	8.18
Net change in Cash	-0.21
Free Cash Flow	6.61

Particulars	MAR 2023 (Values in Cr)
Net Income	1.02
Cash from Operations	0.61
Cash from Investing	-21.76
Cash from Financing	21.82
Net change in Cash	0.22
Free Cash Flow	1.61

Particulars	MAR 2022 (Values in Cr)
Net Income	2.62
Cash from Operations	-2.14
Cash from Investing	-17.75
Cash from Financing	19.84
Net change in Cash	-0.05
Free Cash Flow	-1.24

Particulars	MAR 2021 (Values in Cr)
Net Income	2.75
Cash from Operations	1.90
Cash from Investing	-13.88
Cash from Financing	12.00
Net change in Cash	0.02
Free Cash Flow	2.43

Particulars	MAR 2020 (Values in Cr)
Net Income	2.50
Cash from Operations	-3.18
Cash from Investing	-12.02
Cash from Financing	15.31
Net change in Cash	0.09
Free Cash Flow	-2.51

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
ZENSAR TECHNOLOGIES LTD	634.30	22.27	3.88	14405.55	531.15 / 985.00
WIPRO LTD	239.80	20.25	3.08	251121.82	208.40 / 324.55
INFORMED TECHNOLOGIES INDIA LT	65.65	14.00	1.22	27.38	54.00 / 140.00
PCS TECHNOLOGY LTD.	29.99	52.61	1.40	62.83	23.00 / 44.88

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
ZENSAR TECHNOLOGIES LTD	634.30	25.68	5.19	14405.55	531.15 / 985.00
MIPCO SEAMLESS RINGS (GUJARAT)	37.38	0.00	-4.07	13.40	26.11 / 46.35
WIPRO LTD	239.80	24.27	3.97	251121.82	208.40 / 324.55
INFORMED TECHNOLOGIES INDIA LT	65.65	14.03	1.27	27.38	54.00 / 140.00

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 3.20
26 Days 3.60
10 Days 3.20
50 Days 4.20
12 Days 3.30
100 Days 5.20
20 Days 3.50
200 Days 6.00

3.06
PIVOT

First Resistance	3.10
Second Resistance	3.12
Third Resistance	3.16

First Support	3.04
Second Support	3.00
Third Support	2.98

RSI	26.88
MACD	-0.34
Commodity Channel Index (CCI)	-103.38

ADX	45.85
Williams % R	-91.30

Sgl Resources Limited Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

92.96 Promoter Holdings

7.02 FII

0.0 DII

0.01 Promoter Shares(Pledge Percentage)

17.63

Name	Category	Shares	Shares%
Yogomaya Tradelink Private Limited	Public Shareholding	1.4168122E7	5.66
Vedankit Traders	Public Shareholding	1.3253193E7	5.29
Karnavati Infrastructure Projects Ltd	Shareholding of Promoter and Promoter Group	1.0133499E7	4.05
Comely Electrical Private Limited	Public Shareholding	8726968.0	3.48
Mayur Mukundbhai Desai	Public Shareholding	7461325.0	2.98
Tripurari Deal Trade Private Limited	Public Shareholding	7301380.0	2.91
Balaji Forex (india) Private Limited	Public Shareholding	6961330.0	2.78
Upsilon Trading Llp	Public Shareholding	6580080.0	2.63
Mentax Impex Private Limited	Public Shareholding	6305018.0	2.52
Rajesh Chandubhai Thakkar	Public Shareholding	5818680.0	2.32
Gemzar Enterprises Private Limited	Public Shareholding	5578794.0	2.23
Investino Venture Llp	Public Shareholding	5194157.0	2.07
Morning Vinimay Private Limited	Public Shareholding	4920068.0	1.96
Thakkar Rajesh Chandulal Huf	Public Shareholding	4470712.0	1.78
Blackberry Sarees Private Limited	Public Shareholding	4404591.0	1.76
Theeta Trading Llp	Public Shareholding	4215693.0	1.68
Prashantsinh Ajitsinh Chauhan Huf	Public Shareholding	2655033.0	1.06
Chirag Jayantilal Soni	Shareholding of Promoter and Promoter Group	2205019.0	0.88
Rameshchandra Sojitra	Shareholding of Promoter and Promoter Group	1681989.0	0.67
Vaacha Sojitra	Shareholding of Promoter and Promoter Group	1219063.0	0.49
Vishwas Rameshchandra Sojitra	Shareholding of Promoter and Promoter Group	1165734.0	0.47
Leelavanti R Sojitra	Shareholding of Promoter and Promoter Group	1066577.0	0.43
Rameshchandra K Sojitra Huf	Shareholding of Promoter and Promoter Group	113074.0	0.05

Sgl Resources Limited

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read